| |
Gain expert advice on navigating the stakeholder ecosystem—from payers and policymakers to patients and community oncologists. Download the eBook now to drive commercial success and outcomes in cancer care.
|
|
Today's Big NewsJul 17, 2023 |
| By Nick Paul Taylor Eli Lilly has held the grand reveal of the Alzheimer’s disease trial data it hopes will secure FDA approval for donanemab by the end of the year. The update shows improvements over placebo continued to grow over the course of the study, even after patients stopped taking the drug, but confirmed concerns about safety and the value of treating patients early. |
|
|
|
By Fraiser Kansteiner Sanofi’s immunization scheme is starting to fall into place, thanks to an approval that could propel it and its partner AstraZeneca to the frontlines of the RSV scene. |
By Max Bayer BridgeBio's heart disease drug was victorious in a phase 3 trial, making up for earlier stumbles that threw into question the biotech's cardiorenal aspirations. The company is now planning to submit an approval application to the FDA before the end of the year. |
By Angus Liu Positive phase 3 data could move Johnson & Johnson's lung cancer drug Rybrevant into newly diagnosed patients. And a key phase 3 trial against AstraZeneca's Tagrisso could read out later this year. |
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more.
|
|
By Andrea Park QuidelOrtho is recalling thousands of blood tests used to help quickly diagnose myocardial infarctions and other heart conditions. |
By Max Bayer Sanofi is taking another dip in Scribe's CRISPR pool, inking a new in vivo gene editing partnership worth more than $1.2 billion. The two companies said that one focus of the development pact will be treating sickle cell disease. |
By James Waldron Novartis is getting full rights to the San Diego-based biotech’s FALCON platform as well as a preclinical therapy for Charcot-Marie-Tooth disease type 1A, a neuromuscular disorder for which there are currently no approved meds. |
By Zoey Becker Regeneron's recent FDA rejection of the high-dose Eylea was attributed to manufacturing issues at Catalent's Indiana site, the company confirmed. The observations at the site have now been disclosed, revealing problems related to cleaning and sanitization procedures. |
By Conor Hale The FDA has expanded the use of a drug-coated balloon developed by Urotronic for male urinary procedures, which the company describes as one of the first of a new generation of devices in the space. |
By Gabrielle Masson Westlake Village BioPartners has launched its third fund, a $450 million vault for developing early-stage, next-gen biotechs in Los Angeles and beyond. |
By Andrea Park Fresh off the launch of a second, smaller iteration of its curved intramedullary fixation device, CurvaFix is facing a flood of venture capital—and has tapped a new CEO to help navigate the rising waters. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
